STRIDES ARCOLAB RECEIVES US FDA NOD FOR …
[Pages:2]Press Release Wednesday, April 11, 2012
Strides Arcolab Limited, Strides House, Bannerghatta Road, BBaSnEg:a5lo3r2e5?35160076, India
BSE: 532531 NSE: STAR
STRIDES ARCOLAB RECEIVES US FDA NOD FOR VANCOMYCIN ORAL CAPSULES
? First Wave of generics approvals
April 11, 2012, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received approval from the US FDA for Vancomycin Hydrochloride Capsules USP, 125 mg and 250 mg.
According to IMS health data, Vancomycin Capsules had total U.S. sales of $332m for the twelve months ending Feb-12, with no prior generic approvals.
Arun Kumar, Group CEO of Strides stated that `Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult to manufacture products'.
The product will be launched immediately through Alvogen on a profit share basis.
About Vancomycin
Vancomycin Capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed.
About Strides Arcolab Limited
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 13 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at .
For further information, please contact:
Strides
PR Consultancy
Mr. Manish Gupta, CEO - Pharma +91 80 6784 0112
Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)
Corporate Voice | Weber Shandwick
Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- fidaxomicin versus vancomycin for clostridium
- united states district court for the district of
- fidaxomicin vs vancomycin for clostridium difficile
- stability of vancomycin in syrspend sf
- 510 k substantial equivalence determination
- strides arcolab receives us fda nod for
- vancomycin ii ilex medical
- الصفحة الرئيسية جامعة المنصورة مصر
- niti aayog
- the official web site for the state of new jersey
Related searches
- us companies looking for distributors
- us manufacturers looking for distributors
- us government land for free
- list of latest fda approvals for generics
- fda requirements for cosmetics
- fda guidance for industry
- fda requirements for manufacturing
- fda regulations for food processing
- fda requirements for food manufacturing
- fda guidances for industry
- fda guidance for clinical investigators
- us fda inactive ingredient database